title: Paricalcitol and cardiorenal outcome: from the IMPACT study to clinical practice.
abstract: Chronic kidney disease mineral bone disorders (CKD-MBD) encompass laboratory, vascular and bone abnormalities that might portend a poor prognosis in CKD. In spite of a great effort in elucidating the CKD-MBD natural history and pathogenesis, the underlying mechanisms are still largely unknown. However, a deficit in vitamin D is commonly reported as one of the first steps in CKD-MBD, and numerous epidemiological studies have associated serum vitamin D levels with different markers of cardiovascular disease and the risk of death in different populations. We herein summarize current evidence that links vitamin D deficiency to an adverse outcome and the results of the most recent clinical trials that have investigated the impact of paricalcitol supplementation on hard outcome in CKD patients.
authors.affiliation: Department of Nephrology and Dialysis, Azienda Ospedaliera Sant'Anna, Como, Italy. antonio.bellasi@hsacomo.org
authors.forename: Antonio
authors.initials: A
authors.lastname: Bellasi
authors.forename: Andrea
authors.initials: A
authors.lastname: Galassi
authors.forename: Paolo
authors.initials: P
authors.lastname: Salvi
authors.forename: Mario
authors.initials: M
authors.lastname: Cozzolino
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001851:Bone Diseases, Metabolic / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology*; D002318:Cardiovascular Diseases / Q000150:complications / Q000378:metabolism / Q000473:pathology; D004872:Ergocalciferols / Q000627:therapeutic use*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D051436:Renal Insufficiency, Chronic / Q000150:complications* / Q000188:drug therapy*; D016896:Treatment Outcome; D014807:Vitamin D / Q000378:metabolism
chemical_list: D050071:Bone Density Conservation Agents; D004872:Ergocalciferols; D014807:Vitamin D; C084656:paricalcitol